ID   LD583
AC   CVCL_EJ13
DR   Cosmic; 943747
DR   IARC_TP53; 21073
DR   Wikidata; Q54902368
RX   PubMed=9850064;
RX   PubMed=29732388;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_EJ16 ! LD611
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 19-12-24; Version: 11
//
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//